Physician profile
Millie Das
NPI 1225182322
$151,682.19
in general payments reported to CMS, 2019-2025
29 companies · $48K in 2025
The $48K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,361 · 2020: $6,370 · 2021: $17K · 2022: $9,167 · 2023: $34K · 2024: $32K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Honoraria: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,294 · Travel and Lodging: $4,915 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,987.25 |
| Honoraria | $16,587.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,832.50 |
| Food and Beverage | $6,294.01 |
| Travel and Lodging | $4,914.79 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,966.85 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Jazz Pharmaceuticals INC. | $21,159.31 | 2020-2025 | |
| Novocure INC. | $18,088.71 | 2023-2024 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $15,180.00 | 2023-2025 | Opdivo |
| Janssen Biotech, INC. | $10,981.91 | 2024-2025 | Rybrevant |
| Genzyme Corporation | $10,305.98 | 2021-2023 | |
| Abbvie INC. | $6,085.58 | 2024-2025 | |
| Eli Lilly and Company | $5,200.00 | 2025 | |
| Gilead Sciences, INC. | $4,228.16 | 2023-2025 | Trodelvy |
| Partner Therapeutics, INC. | $4,073.18 | 2024-2025 | Bizengri |
| Astrazeneca Uk Limited | $3,767.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,552.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $3,506.57 | 2023-2025 | Libtayo |
| Emd Serono, INC. | $3,376.91 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $2,996.00 | 2023 | Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,715.89 | 2019-2025 | Tecentriq, Alecensa |
| Catalyst Pharmaceuticals, INC. | $2,412.84 | 2023-2025 | Firdapse |
| Beigene, Ltd. | $1,451.66 | 2021 | |
| Daiichi Sankyo INC. | $1,424.04 | 2023-2025 | Enhertu, Datroway |
| Janssen Scientific Affairs, LLC | $1,350.00 | 2022 | |
| Bristol Myers Squibb Company | $1,287.50 | 2023 | |
| Genentech, INC. | $445.93 | 2022-2025 | Tecentriq, Alecensa, Rozlytrek |
| Zap Surgical Systems, INC. | $53.90 | 2022 | |
| Amgen INC. | $38.83 | 2024 | |
| Adc Therapeutics America, INC. | $17.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.72 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millie Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.